Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication
Authors:
- Peng Foo WongPWPeng Foo Wong
- Lee-Yee ChongLCLee-Yee Chong
- Gerard StansbyGSGerard Stansby
- 6 March 2013
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 309 (9) , 926-927
Abstract
Clinical Question Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality? Bottom Line In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.Keywords
This publication has 6 references indexed in Scilit:
- Antithrombotic Therapy in Peripheral Artery DiseaseChest, 2012
- Antiplatelet agents for intermittent claudicationCochrane Database of Systematic Reviews, 2011
- 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline)JACC, 2011
- The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society GuidelinesCanadian Journal of Cardiology, 2011
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)European Journal of Vascular and Endovascular Surgery, 2007
- Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID studyEuropean Heart Journal, 2004